Smart Inhalers Market - By Product (Dry Powder Inhaler (DPI)-based Smart Inhalers, Metered Dose Inhaler (MDI)-based Smart Inhalers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD)), By Distribution Channel & Forecast, 2022-2028

Industry Overview

Smart Inhalers Market size surpassed USD 1.2 billion in 2021 and is projected to register around 7% CAGR between 2022 and 2028. Growing prevalence rate of several chronic respiratory diseases including asthma and COPD across the globe is one of the major factors contributing to the revenue growth. For instance, as per the World Health Organization report 2019, Asthma is the most common chronic disease found among the children population and around 262 million individuals are affected by asthma.
 

To get more details on this report: Request Free Sample PDF
 

In addition, more than 461,000 have died due to asthma worldwide. Moreover, the adoption of a sedentary lifestyle, smoking habits and high air pollution levels in several countries may lead to several respiratory diseases thereby augmenting the market growth. The continuously rising prevalence of such chronic respiratory diseases has led to an upsurge in the demand for efficient smart inhalers for respiratory care in the past few years thereby, stimulating the adoption of smart inhalers.
 

Although the COVID-19 outbreak has disrupted numerous healthcare activities, the smart inhalers market continued to witness substantial revenue growth. Growing incidence rate of several respiratory complications among COVID-19 patients has propelled market demand. Moreover, a sudden upsurge in patient visits and hospital admissions associated with breathing problems and related chronic diseases led to an increased need for effective respiratory care thereby boosting market demand. Further, an increasing number of COVID-19 patients experiencing side effects such as COPD has resulted in a high disease burden. This has driven the demand for smart inhalers.
 

Smart inhalers are sensor-enabled digital devices utilized for administration of different drugs by inhalation as well as monitoring accurate doses and tracking inhaler usage. These devices include a variety of drugs such as glucocorticoids, anti-cholinergic, and beta-agonists among others. These drugs are used for the prevention and treatment of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Furthermore, smart inhalers help healthcare professionals to monitor patients' health records and routine dose consumption.
 

Steady technological developments offering multiple advantages will propel the industry growth during the projected time

Continuous technological advancements in smart inhalers are expected to proliferate the market statistics in upcoming years. As smart inhalers are part of the new-age digital technology, these devices are being optimized to enhance respiratory ailment management. Enhanced availability of advanced smart inhalers to treat COPD and asthma diseases will fuel market revenue size. These advanced devices offer several benefits such as medication history tracker and monitoring, clinical data collection, enhanced accuracy, and ease of use compared to conventional inhalers thereby, boosting the market growth potential.
 

Adding to this, these devices provide self-management features to the patients as well as miniaturization of sensors for evaluation of inhaled medication volume. Such advantages will drive the industry landscape. Furthermore, the strong presence of key market players that are proactively involved in innovative product development and launches will fuel industry statistics during the anticipated timeframe.
 

Increasing adoption of connected devices and launch of several innovative products will stimulate the product demand

To get more details on this report: Request Free Sample PDF
 

Smart inhalers market by product is segmented into DPI-based smart inhalers and MDI-based smart inhalers. MDI-based smart inhalers segment accounted for more than USD 400 million in revenue in 2021. The segment growth is owing to an increase in respiratory ailments indications and greater effectivity of mechanical smart inhalers diseases in treatment. With a growing patient preference for smart inhalers for self-disease management, the segment is expected to witness higher product demand. Further, DPI based smart inhalers are designed to provide a precise dose of medication as well as patient real-time feedback. Such advantages will offer enormous growth opportunities in the market.
 

Rising prevalence of COPD will accelerate the demand for smart inhalers industry

To get more details on this report: Request Free Sample PDF
 

Smart inhalers market by disease indication is segmented into asthma, and chronic obstructive pulmonary disease (COPD). COPD segment has held around 57% market share in the year 2021 and is projected to hold moderate revenue size over the estimated timeline. Growing COPD patient pool globally will augment the market demand in upcoming years. For instance, according to the World Health Organization, in 2019, over 3.23 million people died due to COPD, and it represents a third leading cause of death globally. Moreover, COPD is caused by several risk factors such as long-term exposure to tobacco smoking, indoor air pollution, harmful gases and particles, and occupational dust are influencing COPD prevalence rate and require constant care management. Thus, the growing prevalence rate of COPD coupled with the rising need for effective treatment will drive segmental demand over the anticipated period.
 

Expanding Sophisticated healthcare infrastructure and accessibility will drive the demand for advanced smart inhalers in hospital settings

Smart inhalers market by distribution channel is segmented into hospital pharmacies, retail pharmacies and E-commerce. The hospital pharmacies segment accounted for considerable market revenue in 2021 and is estimated to proceed at an 7.1% CAGR during the projected timeframe. Expanding the infrastructure of hospital pharmacies in emerging markets will proliferate segmental growth. Moreover, easy accessibility to patients seeking treatment from the hospital is another factor contributing to enhancing revenue growth. Also, enhanced accessibility and product availability is expected to increase the demand for smart inhalers in the settings.
 

High healthcare expenditure and enhanced adoption of advanced technologies in disease management will foster the regional market statistics

North America smart inhalers industry held more than USD 500 million in 2021 and will grow momentously during the analysis timeframe. The growth is primarily attributable to continuous technological advancements in the respiratory disease management industry coupled with the affordability of smart inhalers among the target population is expected to fuel regional smart inhalers market outlook. Additionally, the growing disposable income and high healthcare expenditure on health care management in the region will spur North American market forecasts. Further, the strong presence of established market players and favorable regulatory scenario leads to several product approvals and launches in the region especially in the U.S. Thus, stimulating market size in North America.
 

Collaborations and acquisitions among key industry players will offer enormous growth opportunities to the industry players

Some of the notable key industry players operating in the smart inhalers industry include Adherium, Propeller Health, Nemera, GlaxoSmithKline Plc., Novartis AG, Aptar Group Inc., AstraZeneca Plc, Findair Sp. Z.o.o., BioCorp, Zeolr Technologies Pvt Ltd., Vectura Group Plc., Teva Pharmaceutical Industries Ltd. and Boehringer Ingelheim International GmbH among others. These market participants are implementing various growth strategies such as collaborations, partnerships, acquisitions & mergers, and new product development and launches to strengthen product offerings as well as gain a competitive edge over others.
 

Some of the recent industry developments:

• In July 2020, Novartis has partnered with Propeller to package and ship its enerzair breezhaler with Propeller's digital sensor-enabled tracking platform to treat inadequately controlled asthma patients in Europe. This has strengthened the company’s product portfolio and offered lucrative growth opportunities in the smart inhalers market.
   
• In May 2020, Aptar Pharma has acquired the assets of Cohero Health, a prominent digital company involved in the development of cost-effective digital solutions to improve respiratory care. This has broadened Aptar’s digital portfolio in the respiratory disease management industry, thereby enhancing segment revenue growth.
   

Smart inhalers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028 for the following segments:

Click here to Buy Section of this Report

By Product

• Dry powder inhaler (DPI)-based smart inhalers
• Metered dose inhaler (MDI)-based smart inhalers

By Disease Indication

• Asthma
• Chronic obstructive pulmonary diseases

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • Saudi Arabia
  • Turkey
  • South Africa